Is there a vitamin E paradox?

Ishwarlal Jialal, Maret Traber, Sridevi Devaraj

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

In addition to epidemiologic studies that suggest a benefit for high intakes of α-tocopherol, studies of supplementation in humans have clearly shown that α-tocopherol decreases lipid peroxidation, platelet aggregation, and functions as a potent anti-inflammatory agent. In the five large prospective clinical trials with α-tocopherol therapy, four have shown a beneficial effect on cardiovascular end-points (two studies on a primary end-point and two studies on other cardiovascular end-points). Thus, the totality of evidence based on the epidemiologic data, in-vitro studies and animal models, and the clinical trials appears to support a benefit for α-tocopherol supplementation in patients with pre-existing cardiovascular disease. However, definitive recommendations must await ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)49-53
Number of pages5
JournalCurrent Opinion in Lipidology
Volume12
Issue number1
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Tocopherols
Vitamin E
Clinical Trials
Preexisting Condition Coverage
Platelets
Platelet Aggregation
Lipid Peroxidation
Epidemiologic Studies
Animals
Anti-Inflammatory Agents
Cardiovascular Diseases
Agglomeration
Animal Models
Lipids
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Is there a vitamin E paradox? / Jialal, Ishwarlal; Traber, Maret; Devaraj, Sridevi.

In: Current Opinion in Lipidology, Vol. 12, No. 1, 2001, p. 49-53.

Research output: Contribution to journalArticle

Jialal, I, Traber, M & Devaraj, S 2001, 'Is there a vitamin E paradox?', Current Opinion in Lipidology, vol. 12, no. 1, pp. 49-53. https://doi.org/10.1097/00041433-200102000-00009
Jialal, Ishwarlal ; Traber, Maret ; Devaraj, Sridevi. / Is there a vitamin E paradox?. In: Current Opinion in Lipidology. 2001 ; Vol. 12, No. 1. pp. 49-53.
@article{57ab805e66cb477494e343e5a69833ca,
title = "Is there a vitamin E paradox?",
abstract = "In addition to epidemiologic studies that suggest a benefit for high intakes of α-tocopherol, studies of supplementation in humans have clearly shown that α-tocopherol decreases lipid peroxidation, platelet aggregation, and functions as a potent anti-inflammatory agent. In the five large prospective clinical trials with α-tocopherol therapy, four have shown a beneficial effect on cardiovascular end-points (two studies on a primary end-point and two studies on other cardiovascular end-points). Thus, the totality of evidence based on the epidemiologic data, in-vitro studies and animal models, and the clinical trials appears to support a benefit for α-tocopherol supplementation in patients with pre-existing cardiovascular disease. However, definitive recommendations must await ongoing clinical trials.",
author = "Ishwarlal Jialal and Maret Traber and Sridevi Devaraj",
year = "2001",
doi = "10.1097/00041433-200102000-00009",
language = "English (US)",
volume = "12",
pages = "49--53",
journal = "Current Opinion in Lipidology",
issn = "0957-9672",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Is there a vitamin E paradox?

AU - Jialal, Ishwarlal

AU - Traber, Maret

AU - Devaraj, Sridevi

PY - 2001

Y1 - 2001

N2 - In addition to epidemiologic studies that suggest a benefit for high intakes of α-tocopherol, studies of supplementation in humans have clearly shown that α-tocopherol decreases lipid peroxidation, platelet aggregation, and functions as a potent anti-inflammatory agent. In the five large prospective clinical trials with α-tocopherol therapy, four have shown a beneficial effect on cardiovascular end-points (two studies on a primary end-point and two studies on other cardiovascular end-points). Thus, the totality of evidence based on the epidemiologic data, in-vitro studies and animal models, and the clinical trials appears to support a benefit for α-tocopherol supplementation in patients with pre-existing cardiovascular disease. However, definitive recommendations must await ongoing clinical trials.

AB - In addition to epidemiologic studies that suggest a benefit for high intakes of α-tocopherol, studies of supplementation in humans have clearly shown that α-tocopherol decreases lipid peroxidation, platelet aggregation, and functions as a potent anti-inflammatory agent. In the five large prospective clinical trials with α-tocopherol therapy, four have shown a beneficial effect on cardiovascular end-points (two studies on a primary end-point and two studies on other cardiovascular end-points). Thus, the totality of evidence based on the epidemiologic data, in-vitro studies and animal models, and the clinical trials appears to support a benefit for α-tocopherol supplementation in patients with pre-existing cardiovascular disease. However, definitive recommendations must await ongoing clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0035140569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035140569&partnerID=8YFLogxK

U2 - 10.1097/00041433-200102000-00009

DO - 10.1097/00041433-200102000-00009

M3 - Article

C2 - 11176203

AN - SCOPUS:0035140569

VL - 12

SP - 49

EP - 53

JO - Current Opinion in Lipidology

JF - Current Opinion in Lipidology

SN - 0957-9672

IS - 1

ER -